INM - InMed Pharmaceuticals Inc.
IEX Last Trade
4.29
0 0%
Share volume: 0
Last Updated: Fri 27 Dec 2024 08:30:16 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$4.29
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.92%
1 Month
6.74%
3 Months
1,876.74%
6 Months
1,600.00%
1 Year
1,070.92%
2 Year
240.00%
Key data
Stock price
$4.29
DAY RANGE
$0.27 - $4.22
52 WEEK RANGE
$0.14 - $6.40
52 WEEK CHANGE
$1,003.37
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Eric A. Adams
Region: US
Website: inmedpharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: inmedpharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
InMed Pharmaceuticals Inc. researches and develops cannabinoid-based therapies. Lead product INM-755, a cannabinoidol topical cream, is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing InM-088, which is in preclinical studies for the. treatment of glaucoma and pain.
Recent news